Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3109285 | 0.94 | TSHR (0.43) | TSHRALDH1A1TDP1CYP3A4HCAR2 | |
| SCHEMBL27855347 | 0.91 | TSHR (0.46) | TSHRALDH1A1TDP1CYP3A4HCAR2 | |
| SCHEMBL3099499 | 0.91 | TSHR (0.46) | TSHRALDH1A1TDP1CYP3A4HCAR2 | |
| SCHEMBL34343 | 0.87 | THRB (0.37) | TSHRALDH1A1TDP1 | |
| SCHEMBL10952662 | 0.86 | CAMK2A (0.38) | TSHRALDH1A1TDP1CYP3A4HCAR2 | |
| SCHEMBL1948952 | 0.84 | ALDH1A1 (0.58) | TSHRALDH1A1TDP1HCAR2ATM | |
| SCHEMBL27379280 | 0.84 | ACHE (0.41) | TSHRALDH1A1TDP1CYP3A4HCAR2 | |
| SCHEMBL1401947 | 0.84 | ALDH1A1 (0.58) | TSHRALDH1A1TDP1HCAR2ATM | |
| Hydrochloric Acid SCHEMBL10892981 | 0.82 | ALDH1A1 (0.56) | TSHRALDH1A1TDP1HCAR2ATM | |
| SCHEMBL1401944 | 0.82 | ALDH1A1 (0.56) | TSHRALDH1A1TDP1HCAR2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111568-A1 | LUMATEPERONE AND ANALOGUES, AS 5-HT2A OR 5-HT2A/D2 RECEPTOR MODULATORS, FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS CAUSED BY VIRAL, BACTERIAL, OR AUTOIMMUNE ENCEPHALITIS, AND OF PSYCHIATRIC SYMPTOMS THEREOF | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4525874-A1 | NOVEL METHODS | Intra-Cellular Therapies, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4493560-A2 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023225620-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023178111-A2 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-4072554-A1 | ORGANIC COMPOUND | Intra-Cellular Therapies, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021119334-A1 | ORGANIC COMPOUND | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-3768271-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3768254-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10632079-B2 | Microspheres having core/shell structure | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2020-04-28 | — | — | US | disclosed |
| EP-1418887-A1 | HEPARIN STENT | Zoucas Kirurgkonsult AB (SE) | 2004-05-19 | — | — | EP | disclosed |
| US-20040052854-A1 | Porous substances and methods for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1023044-B1 | APATITE-COATED SOLID COMPOSITION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-02-04 | — | — | EP | disclosed |
| EP-1354581-A1 | POROUS SUBSTANCE AND PROCESS FOR PRODUCING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| WO-2003011250-A1 | HEPARIN STENT | ZOUCAS KIRURGKONSULT AB (SE) | 2003-02-13 | — | — | WO | disclosed |
| EP-1251902-A1 | MEDICAL DEVICE | Zoucas Kirurgkonsult AB (SE) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001056646-A1 | MEDICAL DEVICE | ZOUCAS KIRURGKONSULT AB (SE) | 2001-08-09 | — | — | WO | disclosed |
| EP-0353961-B1 | Thermoplastic elastomer-based low vulnerability ammunition gun propellants | THIOKOL CORP (US) | 1995-12-27 | — | — | EP | disclosed |
| US-4919737-A | NON-CROSSLINKED, RESIDUE-FREE BINDER CONTAINING AMORPHOUS POLYETHER AND CRYSTALLINE POLYESTER BLOCKS | MORTON THIOKOL INC. (US) | 1990-04-24 | — | — | US | disclosed |
| EP-0353961-A2 | Thermoplastic elastomer-based low vulnerability ammunition gun propellants | THIOKOL CORPORATION (US) | 1990-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040052854-A1 | Porous substances and methods for producing the same | PGF, TACR1, CA3 | TSHR 2307/4885ALDH1A1 2293/4885TDP1 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.